RAPT Therapeutics Highlights Early Results for RPT193 at Society for Investigative Dermatology Meeting
15 May 2020 - 10:00PM
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage,
immunology-based biopharmaceutical company focused on
discovering, developing and commercializing oral small molecule
therapies for patients with significant unmet needs in oncology and
inflammatory diseases, today announced that researchers presented
encouraging results from preclinical and healthy volunteer studies
for RPT193 at the Society for Investigative Dermatology (SID)
Meeting. RPT193 is a small molecule, once-daily oral therapy in
development for the treatment of atopic dermatitis and other
allergic inflammatory diseases.
During the session, Laurence Cheng, M.D., Ph.D., Senior Medical
Director at RAPT Therapeutics, presented blinded Phase 1a data from
healthy volunteer cohorts of an ongoing seamless Phase 1 study
showing that once-daily oral dosing of RPT193 for seven days
achieved target drug levels and target coverage with an excellent
safety profile in healthy volunteers. In addition, Dr. Cheng noted
that in multiple preclinical studies of allergic skin inflammation,
once-daily dosing of RPT193 demonstrated efficacy and reduction of
Th2 cytokines comparable to treatment with currently available
biologics that work by blocking interleukin-4 (IL-4) and IL-13, the
major drivers of allergic inflammatory disease.
“Taken together, our healthy volunteer data along with our
preclinical studies strongly suggest that by blocking the migration
of Th2 cells into the inflamed skin, RPT193 may be able to reduce
or eliminate allergic inflammation in patients with atopic
dermatitis in a safe and convenient manner,” said Brian Wong, M.D.,
Ph.D., President and CEO of RAPT Therapeutics. “Our next step is to
complete the Phase 1b portion of the study in patients with atopic
dermatitis to establish clinical proof-of-concept before moving
into a Phase 2 study.”
To view the presentation live at 3:30pm ET, please register
using this link. An archived copy of the presentation can be
accessed on the RAPT website under the Events and Presentation tab
of the Investor Relations section here after 4pm ET.
About RPT193RPT193 is a small molecule,
once-daily oral therapy in development for the treatment of atopic
dermatitis and other allergic inflammatory diseases. RPT193 is
designed to selectively inhibit the migration of Th2 cells into
allergically-inflamed tissues in order to break the cycle of
inflammation driving disease. RPT193 blocks CCR4, a receptor highly
expressed on Th2 cells. In allergic inflammatory diseases,
including atopic dermatitis, chemokines recruit Th2 cells via CCR4
into inflamed tissues. Once Th2 cells enter inflamed tissues such
as the skin or the airways in the lung, they secrete proteins known
to further drive the inflammatory response. The role of these Th2
cell-derived proteins has been clinically validated by injectable
biologics targeting this pathway. Patients with atopic dermatitis
express higher levels of CCR4 ligands compared with healthy humans;
these ligands also correlate with the severity and activity of
disease. RAPT believes that by inhibiting CCR4, RPT193 has the
potential to bring therapeutic benefit to patients across a broad
spectrum of additional allergic inflammatory diseases, including
asthma, chronic urticaria, allergic conjunctivitis, chronic
rhinosinusitis and eosinophilic esophagitis. Following successful
completion of the Phase 1b study in atopic dermatitis, RAPT expects
to expand clinical development into additional Th2-driven allergic
indications.
About RAPT Therapeutics, Inc.RAPT
Therapeutics is a clinical stage immunology-based biopharmaceutical
company focused on discovering, developing and commercializing oral
small molecule therapies for patients with significant unmet needs
in oncology and inflammatory diseases. Utilizing its proprietary
discovery and development engine, the Company is developing highly
selective small molecules designed to modulate the critical immune
drivers underlying these diseases. RAPT has discovered and advanced
two unique drug candidates, FLX475 and RPT193, each targeting C-C
motif chemokine receptor 4 (CCR4), for the treatment of cancer and
inflammation, respectively. The Company is also pursuing a range of
targets, including hematopoietic progenitor kinase 1 (HPK1) and
general control nonderepressible 2 (GCN2), that are in the
discovery stage of development.
Forward-Looking StatementsThis press release
contains forward-looking statements. These statements relate to
future events and involve known and unknown risks, uncertainties
and other factors that may cause our actual results, performance or
achievements to be materially different from any future
performances or achievements expressed or implied by the
forward-looking statements. Each of these statements is based only
on current information, assumptions and expectations that are
inherently subject to change and involve a number of risks and
uncertainties. Forward-looking statements include, but are not
limited to, statements about the clinical development of RPT193.
Detailed information regarding risk factors that may cause actual
results to differ materially from the results expressed or implied
by statements in this press release may be found in RAPT’s Form
10-Q filed with the Securities and Exchange Commission on May 14,
2020 and subsequent filings made by RAPT with the Securities and
Exchange Commission. These forward-looking statements speak only as
of the date hereof. RAPT disclaims any obligation to update these
forward-looking statements.
RAPT Media Contact:Angela
Bittingmedia@rapt.com(925) 202-6211
RAPT Investor Contact:Sylvia
Wheelerswheeler@wheelhouselsa.com
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Apr 2024 to May 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From May 2023 to May 2024